Selexis SA and Xencor sign 4 Commercial License Agreements
26.02.2018
Share this article
On 26 February, Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates
Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, today announced that it has signed four commercial license agreements (CLAs) with Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. The CLAs extend the companies’ previous agreement through which Selexis is providing Xencor with access to its SUREtechnology Platform™, as well as cell line development-related services that include personnel, laboratory equipment and laboratory space.